Lundbeck Has Good First Quarter But European Price Cut Fears Cloud Outlook
This article was originally published in The Pink Sheet Daily
Executive Summary
Lundbeck's sales rose by 15 percent and its operating profits increased by 32 percent in the first quarter
You may also be interested in...
Is Neurotech's Search For Highly-Focused Targets Holding Up Drug Development In The Field?
The issue of whether a start-up should know its compound's mechanism of action before it knocks on a VC's door became an ongoing topic of conversation at the Neurotech Investing conference in Boston.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.